Inflammation-Driven Dermal Lymphangiogenesis in Atopic Dermatitis is Associated with CD11b+ Macrophage Recruitment and VEGF-C Up-regulation in the IL-4-Transgenic Mouse Model

Microcirculation

Volumn 19, Issue 7, 2012, Pages 567-579

  Shi, Vivian Y ^a   Bao, Lei ^a   Chan, Lawrence S ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Atopic dermatitis; Inflammation; Lymphangiogenesis; Macrophage; Skin; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CD11B ANTIGEN; GROWTH FACTOR; INTERLEUKIN 4; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PODOPLANIN; RECEPTOR; RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; DISEASE COURSE; EPIDERMIS CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; MACROPHAGE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD11B; CELLS, CULTURED; CHEMOKINE CCL2; DERMATITIS, ATOPIC; DERMIS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-4; LYMPHANGIOGENESIS; MACROPHAGES; MICE; MICE, TRANSGENIC; RIBONUCLEASE, PANCREATIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; VESICULAR TRANSPORT PROTEINS;

EID: 84867359105     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/j.1549-8719.2012.00189.x     Document Type: Article

References (94)

1. Agha-Majzoub R, Becker RP, Schraufnagel DE, Chan LS. Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. Microcirculation12: 455-476, 2005.
2. Al Robaee AA, Shahzad M. Impairment quality of life in families of children with atopic dermatitis. Acta Dermatovenerol Croat18: 243-247, 2010.
3. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature438: 946-953, 2005.
4. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol10: 165-177, 2009.
5. Bahram F, Claesson-Welsh L. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology17: 253-261, 2010.
6. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Yla-Herttuala S, Jackson DG, Alitalo K, McDonald DM. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest115: 247-257, 2005.
7. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D. Podoplanin, novel 43-kD membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol151: 1141-1152, 1997.
8. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol22: 192-199, 2005.
9. Chaitanya GV, Franks SE, Cromer W, Wells SR, Bienkowska M, Jennings MH, Ruddell A, Ando T, Wang Y, Gu Y, Sapp M, Mathis JM, Jordan PA, Minagar A, Alexander JS. Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro. Lymphat Res Biol8: 155-164, 2010.
10. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol117: 977-983, 2001.
11. Chen L, Lin SX, Amin S, Overbergh L, Maggiolino G, Chan LS. VCAM-1 blockade delays disease onset, reduces disease severity and inflammatory cells in an atopic dermatitis model. Immunol Cell Biol88: 334-342, 2010.
12. Chen L, Marble DJ, Agha R, Peterson JD, Becker RP, Jin T, Li J, Chan LS. The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4-transgenic model of atopic dermatitis. Microcirculation15: 49-64, 2008.
13. Chen L, Martinez O, Venkataramani P, Lin SX, Prabhakar BS, Chan LS. Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol139: 189-201, 2005.
14. Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L, Dana R. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol175: 1984-1992, 2009.
15. Cliff S, Bedlow AJ, Stanton AW, Mortimer PS. An in vivo study of the microlymphatics in psoriasis using fluorescence microlymphography. Br J Dermatol140: 61-66, 1999.
16. Cueni LN, Chen L, Zhang H, Marino D, Huggenberger R, Alitalo A, Bianchi R, Detmar M. Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin. Blood116: 4376-4384, 2010.
17. Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol126: 2167-2177, 2006.
18. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest113: 1040-1050, 2004.
19. Cushing SD, Fogelman AM. Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein. Arterioscler Thromb12: 78-82, 1992.
20. Davis JS, Yeo TW, Piera KA, Woodberry T, Celermajer DS, Stephens DP, Anstey NM. Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity. Crit Care14: R89, 2010.
21. De Palma M, Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin Cancer Res17: 5226-5232, 2011.
22. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Allergy Asthma Rep9: 265-272, 2009.
23. Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm8: 333-342, 2002.
24. Flister MJ, Wilber A, Hall KL, Iwata C, Miyazono K, Nisato RE, Pepper MS, Zawieja DC, Ran S. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood115: 418-429, 2010.
25. Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G. The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective. Manag Care Interface20: 26-32, 2007.
26. Galland F, Karamysheva A, Pebusque MJ, Borg JP, Rottapel R, Dubreuil P, Rosnet O, Birnbaum D. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene8: 1233-1240, 1993.
27. Gordon EJ, Rao S, Pollard JW, Nutt SL, Lang RA, Harvey NL. Macrophages define dermal lymphatic vessel calibre during development by regulating lymphatic endothelial cell proliferation. Development137: 3899-3910, 2010.
28. Hamada K, Oike Y, Takakura N, Ito Y, Jussila L, Dumont DJ, Alitalo K, Suda T. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood96: 3793-3800, 2000.
29. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest94: 870-876, 1994.
30. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol98: 225-231, 1996.
31. Henno A, Blacher S, Lambert CA, Deroanne C, Noel A, Lapiere C, de la Brassinne M, Nusgens BV, Colige A. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. J Dermatol Sci57: 162-169, 2010.
32. Hirasawa Y, Takai T, Nakamura T, Mitsuishi K, Gunawan H, Suto H, Ogawa T, Wang XL, Ikeda S, Okumura K, Ogawa H. Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J Invest Dermatol130: 614-617, 2010.
33. Holopainen T, Bry M, Alitalo K, Saaristo A. Perspectives on lymphangiogenesis and angiogenesis in cancer. J Surg Oncol103: 484-488, 2011.
34. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, Schneider L, Beck LA, Barnes KC, Leung DY. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol120: 150-155, 2007.
35. Hubbard NE, Lim D, Mukutmoni M, Cai A, Erickson KL. Expression and regulation of murine macrophage angiopoietin-2. Cell Immunol234: 102-109, 2005.
36. Huggenberger R, Siddiqui SS, Brander D, Ullmann S, Zimmermann K, Antsiferova M, Werner S, Alitalo K, Detmar M. An important role of lymphatic vessel activation in limiting acute inflammation. Blood117: 4667-4678, 2011.
37. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar M. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med207: 2255-2269, 2010.
38. Ikoma A. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mechanisms and management of itch in atopic dermatitis. J Pharmacol Sci110: 265-269, 2009.
39. Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res68: 1100-1109, 2008.
40. Ji RC. Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis. Cell Mol Life Sci69: 897-914, 2012.
41. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J15: 1751, 1996.
42. Kaneko MK, Kato Y, Kameyama A, Ito H, Kuno A, Hirabayashi J, Kubota T, Amano K, Chiba Y, Hasegawa Y, Sasagawa I, Mishima K, Narimatsu H. Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett581: 331-336, 2007.
43. Kaneko M, Kato Y, Kunita A, Fujita N, Tsuruo T, Osawa M. Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells. J Biol Chem279: 38838-38843, 2004.
44. Kataru RP, Jung K, Jang C, Yang H, Schwendener RA, Baik JE, Han SH, Alitalo K, Koh GY. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood113: 5650-5659, 2009.
45. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, Fivenson D. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol41: 151-158, 2002.
46. Kim KE, Koh YJ, Jeon BH, Jang C, Han J, Kataru RP, Schwendener RA, Kim JM, Koh GY. Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm. Am J Pathol175: 1733-1745, 2009.
47. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol126: 332-337, 2008.
48. Kluger MS, Colegio OR. Lymphangiogenesis linked to VEGF-C from tumor-associated macrophages: accomplices to metastasis by cutaneous squamous cell carcinoma?J Invest Dermatol131: 17-19, 2011.
49. Kragballe KTopical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh)151: 7-10, 1989. discussion 47-52.
50. Kurahashi R, Hatano Y, Katagiri K. IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. J Invest Dermatol128: 1329-1331, 2008.
51. Lawrence T, Gilroy DW. Chronic inflammation: a failure of resolution?Int J Exp Pathol88: 85-94, 2007.
52. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol2: 787-795, 2002.
53. Liersch R, Detmar M. Lymphangiogenesis in development and disease. Thromb Haemost98: 304-310, 2007.
54. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med193: 727-740, 2001.
55. Lin YT, Wang CT, Chiang BL. Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol33: 167-177, 2007.
56. Liu NF, He QL. The regulatory effects of cytokines on lymphatic angiogenesis. Lymphology30: 3-12, 1997.
57. Maintz L, Novak N. Modifications of the innate immune system in atopic dermatitis. J Innate Immun3: 131-141, 2011.
58. Maruyama K, Asai J, Ii M, Thorne T, Losordo DW, D'Amore PA. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol170: 1178-1191, 2007.
59. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, D'Amore PA, Stein-Streilein J, Losordo DW, Streilein JW. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest115: 2363-2372, 2005.
60. McIntyre TM, Prescott SM, Weyrich AS, Zimmerman GA. Cell-cell interactions: leukocyte-endothelial interactions. Curr Opin Hematol10: 150-158, 2003.
61. Morisada T, Oike Y, Yamada Y, Urano T, Akao M, Kubota Y, Maekawa H, Kimura Y, Ohmura M, Miyamoto T, Nozawa S, Koh GY, Alitalo K, Suda T. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood105: 4649-4656, 2005.
62. Moussai D, Mitsui H, Pettersen JS, Pierson KC, Shah KR, Suarez-Farinas M, Cardinale IR, Bluth MJ, Krueger JG, Carucci JA. The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. J Invest Dermatol131: 229-236, 2011.
63. Navid F, Kolbe L, Stab F, Korff T, Neufang G. UV radiation induces the release of angiopoietin-2 from dermal microvascular endothelial cells. Exp Dermatol21: 147-153, 2012.
64. Nightingale TD, Frayne ME, Clasper S, Banerji S, Jackson DG. A mechanism of sialylation functionally silences the hyaluronan receptor LYVE-1 in lymphatic endothelium. J Biol Chem284: 3935-3945, 2009.
65. Rahier JF, De Beauce S, Dubuquoy L, Erdual E, Colombel JF, Jouret-Mourin A, Geboes K, Desreumaux P. Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Aliment Pharmacol Ther34: 533-543, 2011.
66. Ramot B, Ben-Bassat I. Environment and malignancies of the lymphatic system. Princess Takamatsu Symp18: 87-94, 1987.
67. Rehal B, Armstrong A. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS ONE6: e17520, 2011.
68. Reichle ME, Chen L, Lin SX, Chan LS. The Th2 systemic immune milieu enhances cutaneous inflammation in the K14-IL-4-transgenic atopic dermatitis model. J Invest Dermatol131: 791-794, 2011.
69. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol27: 555-561, 2002.
70. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol216: 347-354, 2008.
71. Ryan TJ, Curri SB. Blood vessels and lymphatics. Clin Dermatol7: 25-36, 1989.
72. Saito H. Much atopy about the skin: genome-wide molecular analysis of atopic eczema. Int Arch Allergy Immunol137: 319-325, 2005.
73. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol161: 947-956, 2002.
74. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J21: 325-332, 2007.
75. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol6: 1191-1197, 2005.
76. Shantha Kumara HM, Hoffman A, Kim IY, Feingold D, Dujovny N, Kalady M, Luchtefeld M, Whelan RL. Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels. Surg Endosc23: 409-415, 2009.
77. Shao X, Liu C. Influence of IFN- alpha and IFN- gamma on lymphangiogenesis. J Interferon Cytokine Res26: 568-574, 2006.
78. Shao XJ, Lu WQ, Liu C. Different effects of angiogenesis inhibitors IFN-alpha and TIMP-1 on lymphangiogenesis. Lymphology41: 64-74, 2008.
79. Shimamura K, Nakatani T, Ueda A, Sugama J, Okuwa M. Relationship between lymphangiogenesis and exudates during the wound-healing process of mouse skin full-thickness wound. Wound Repair Regen17: 598-605, 2009.
80. Shimoda H. Immunohistochemical demonstration of angiopoietin-2 in lymphatic vascular development. Histochem Cell Biol131: 231-238, 2009.
81. Stacker SA, Farnsworth RH, Karnezis T, Shayan R, Smith DP, Paavonen K, Davydova N, Caesar C, Inder R, Baldwin ME, McColl BK, Roufail S, Williams RA, Hughes RA, Alitalo K, Achen MGMolecular pathways for lymphangiogenesis and their role in human disease. Novartis Found Symp281: 38-43, 2007; discussion 44-53, 208-209.
82. Staton CA, Valluru M, Hoh L, Reed MW, Brown NJ. Angiopoietin-1, angiopoietin-2 and Tie-2 receptor expression in human dermal wound repair and scarring. Br J Dermatol163: 920-927, 2010.
83. Swartz MA, Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech55: 92-99, 2001.
84. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell140: 460-476, 2010.
85. Trompezinski S, Berthier-Vergnes O, Denis A, Schmitt D, Viac J. Comparative expression of vascular endothelial growth factor family members, VEGF-B, -C and -D, by normal human keratinocytes and fibroblasts. Exp Dermatol13: 98-105, 2004.
86. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res10: 7965-7971, 2004.
87. van der Veer WM, Niessen FB, Ferreira JA, Zwiers PJ, de Jong EH, Middelkoop E, Molema G. Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. Wound Repair Regen19: 292-301, 2011.
88. Wittkowski A, Richards HL, Griffiths CE, Main CJ. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res57: 195-200, 2004.
89. Yamada Y, Nezu J, Shimane M, Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics42: 483-488, 1997.
90. Yan ZX, Jiang ZH, Liu NF. Angiopoietin-2 promotes inflammatory lymphangiogenesis and its effect can be blocked by the specific inhibitor L1-10. Am J Physiol Heart Circ Physiol302: H215-H223, 2012.
91. Yun SJ, Gimotty PA, Hwang WT, Dawson P, Van Belle P, Elder DE, Elenitsas R, Schuchter L, Zhang PJ, Guerry D, Xu X. High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma. Am J Surg Pathol35: 235-242, 2011.
92. Zhang Q, Lu Y, Proulx ST, Guo R, Yao Z, Schwarz EM, Boyce BF, Xing L. Increased lymphangiogenesis in joints of mice with inflammatory arthritis. Arthritis Res Ther9: R118, 2007.
93. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol214: 161-178, 2008.
94. Zhang B, Wang J, Gao J, Guo Y, Chen X, Wang B, Rao Z, Chen Z. Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma. J Cell Biochem107: 134-143, 2009.